Akeso Shares Plunge 22% as Ivonescimab Fails to Win U.S. Approval; Xia Yu Calls It the Most Disheartening Moment in 14 Years

Deep News11-16

Hong Kong-listed Akeso (09926.HK) saw its shares plunge 22% today, closing at HK$64.1 and giving the company a market value of HK$60.3 billion.

The core reason behind the sharp decline is that Akeso's partner Summit Therapeutics Inc. (NASDAQ: SMMT) recently announced that the U.S. Food and Drug Administration (FDA) declined to approve the launch of the novel PD-1 x VEGF bispecific antibody Ivonescimab.

The FDA's rationale was that there is a lack of a statistically significant improvement in overall survival (OS), and there is currently insufficient evidence to prove its efficacy.

The FDA stated that in the absence of a statistically significant OS benefit, a progression-free survival (PFS) benefit alone is not enough to support the "benefit-risk" assessment required for approval.

Akeso and Summit have a deep partnership. In December 2022, Akeso licensed part of the overseas rights to Ivonescimab to U.S.-based Summit in a record-setting deal worth US$5 billion (US$500 million upfront) plus a double-digit percentage sales royalty and equity in the partner.

After the news of Ivonescimab's U.S. approval failure was announced, Summit's shares plunged 20% in after-hours trading, and Akeso, as a key partner, could hardly escape the fallout.

Xia Yu Calls It the Most Disheartening Moment in 14 Years of Entrepreneurship

Akeso founder and CEO Dr. Xia Yu held an emergency conference call yesterday to reassure investors.

Xia Yu said the news was extremely disheartening and marked the most disheartening moment for her since Akeso was founded 14 years ago. Over the past 14 years, Akeso's development in oncology and non-oncology fields had been relatively fortunate, but this is indeed a major setback.

According to her, Akeso began cooperating with Summit in 2022. Due to the time gap in patient enrollment between China and overseas, and because Ivonescimab was then "little known" overseas and had never been used in Western patients, overseas enrollment was extremely difficult.

Currently, in this indication, none of the products approved by the FDA have obtained approval based on statistically significant OS.

Xia Yu believes Summit made a very bold move by submitting the BLA after comprehensively assessing the room for improvement in toxicity and side effects among existing treatment options. After submission, Summit continued to conduct OS analyses. Unfortunately, under clinical research standards, once the formal analysis is completed, subsequent post-hoc analyses lose their statistical validity. Even if long-term follow-up of Western patients later yields a "nominal significance" of HR=0.76, it is no longer a formal analysis.

"Although post-hoc analysis data were submitted, unfortunately the FDA did not compromise on this standard. Summit's press release conclusion is very clear: the lack of a statistically significant OS benefit cannot support approval. This is a very clear regulatory stance," Xia Yu said. She added that in the past, when there was good news, the stock price would fluctuate; now, in the face of bad news, the company is prepared, and if severe volatility occurs, it will take measures including "buybacks" to stabilize the market and protect shareholders' rights.

Xia Yu also comforted investors, saying this may be a "Special Case" and does not mean the entire PD-1/VEGF bispecific antibody track is blocked. She sincerely hopes and firmly believes that this is only a very small event in the company's development history. Compared with 2022, today's Akeso has undergone earth-shaking changes, with multiple products entering the commercialization stage.

Just Completed HK$1.9 Billion Placement

Although Xia Yu expressed dismay and reassured investors, Akeso completed a placement a month ago on the news that Summit's Ivonescimab might be approved in the U.S., raising HK$1.9 billion.

The placement shares will account for approximately 2.17% of the company's existing issued share capital as of the date of the announcement and approximately 2.13% of the company's enlarged issued share capital immediately after completion of the placement.

Before the transaction, Dr. Xia Yu controlled 10.96% of the equity, Dr. Li Baiyong controlled 5.34%, Dr. Wang Zhongmin controlled 4.65%, and Dr. Zhang Peng controlled 3.51%. After the transaction is completed, Dr. Xia Yu controls 10.73%, Dr. Li Baiyong controls 5.22%, Dr. Wang Zhongmin controls 4.55%, and Dr. Zhang Peng controls 3.43%.

In fact, Summit also secured US$2 billion in financing from AstraZeneca in September 2026 on the strength of Ivonescimab.

First-Half Revenue of 1.8 Billion Yuan, Net Loss of 400 Million Yuan

Financial statements show that Akeso's revenue in the first half of 2026 was 1.8 billion yuan, up 28.65% from 1.4 billion yuan in the same period last year. The growth was mainly driven by sales contributions from two oncology immunotherapy bispecific products, Cadonilimab (PD-1/CTLA-4) and Ivonescimab (PD-1/VEGF); market promotion activities for commercialized products in the non-oncology field were gradually rolled out in an orderly manner, and sales gradually increased.

Akeso's gross profit in the first half of 2026 was 1.34 billion yuan, compared with 1.121 billion yuan in the first half of 2025.

Akeso's loss for the period in the first half of 2026 was 447 million yuan, compared with a loss of 588 million yuan in the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment